The primary purpose of the study is to demonstrate a blood pressure lowering effect of
CasiGold and CasiMax in subjects with high-normal blood pressure or mild hypertension. The
secondary purpose is to collect human safety data after treatment with CasiGold and CasiMax,
to gain insight into potential mechanisms by measurement of renin and angiotensin I and II,
and to evaluate the genetic determinants of the individual BP lowering response by
measurement of specific genetic polymorphisms.